Subtype
Intestinal Carcinoma
CI-CAN-00002922Explore in graph →
409 active trials5 approved drugs22 evidence items
- NCIt
- C227934
Loading cancer entity…
Subtype
CI-CAN-00002922Explore in graph →
Clinical trials
1,268 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (150)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00005049 | Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer | completed | Phase 2 | 45 | NYU Langone HealthOTHER | 1 | Apr 6, 2011 | clinicaltrials |
| NCT00005804 | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00964457 |
| Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients |
| unknown |
| Phase 2 |
| 60 |
| Copenhagen University Hospital at HerlevOTHER |
| 1 |
| Aug 25, 2009 |
| clinicaltrials |
| NCT00107861 | Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases | completed | Phase 1 / Phase 2 | 44 | BiogenINDUSTRY | 1 | Jul 14, 2009 | clinicaltrials |
| NCT00051987 | Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma | completed | Phase 2 | 175 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00165217 | Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma | completed | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00557713 | XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma | unknown | Phase 2 | 44 | Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socialsOTHER | 1 | Nov 14, 2007 | clinicaltrials |
| NCT00215722 | XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer | unknown | Phase 2 | 45 | Grupo de Investigacao do Cancro DigestivoOTHER | 1 | Apr 6, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2011source: clinicaltrials